HCA Warning, Leqembi, Insulin, ICER

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning. The hospital access signals are particularly timely.

MarcusSame here. We're looking at HCA's profit warning and what it means for healthcare access — the system sustainability angle is critical right now. Then subQ Leqembi's approval and its HEOR implications — this could redefine Alzheimer's value frameworks. And the FTC settlement with CVS Caremark over insulin pricing — that's a direct market access pivot point.

SaraThat second one is interesting to me — the budget impact question there is one the field hasn't fully worked out yet. Subcutaneous administration changes real-world adherence patterns, which complicates cost modeling.

MarcusExactly. And we'll also cover ICER's expanded scientific advice program — they're really pushing the boundaries of early evidence generation. Let's get into it.

MarcusStarting with HCA's profit warning. The largest US hospital chain reporting significant margin pressure signals deeper systemic issues. This isn't just about HCA — it's a bellwether for hospital financial health across the board, directly impacting drug access decisions.

SaraThat's one read — I'd frame it slightly differently. What strikes me is how this connects to formulary restrictions. When hospitals face margin squeezes, they accelerate step therapy requirements and tighten specialty drug prior authorization. The access bottleneck shifts from payers to providers.

MarcusThat's fair, though I think payers would see it differently. The real story here is the cascading effect: hospital financial stress leads to shorter stays, reduced diagnostic testing, and ultimately earlier discharge to outpatient settings. That changes the entire evidence generation landscape for drugs with inpatient administration requirements.

SaraThe part that gives me pause is the timing. This isn't just post-pandemic adjustment — it's structural. Medicare reimbursement pressures combined with labor costs are creating a permanent squeeze. We're seeing hospital networks consolidate, which concentrates access decision-making in fewer, more financially constrained hands.

MarcusExactly, and what's interesting is how this intersects with value-based contracting. Hospitals are now more likely to demand outcomes-based agreements tied to reduced readmissions. That's a fundamental shift from traditional pay-for-performance models. The HEOR evidence requirements just got more complex.

SaraI wonder if that's the full picture though. The financial pressure also means hospitals are more receptive to bundled payment models that include drugs. For manufacturers, this could open doors for innovative contracting if they can demonstrate total cost of ownership savings.

MarcusThat connects to something I keep coming back to: the patient journey is becoming increasingly fragmented. When hospitals cut lengths of stay, the burden shifts to home care and primary providers. We need real-world evidence that captures these transitions. The evidence strategy must now span multiple care settings.

SaraMoving to subQ Leqembi. The FDA's approval for subcutaneous administration is significant — it fundamentally changes the treatment paradigm for Alzheimer's patients who've struggled with IV infusions. This isn't just a delivery route change; it's a game-changer for real-world adherence.

MarcusI'd push back slightly on that characterization. While administration ease improves, the core clinical evidence remains unchanged. The pivotal trial data was for IV administration. The HEOR community now faces a critical question: how do we value convenience without new efficacy data? That's a methodological minefield.

SaraThat's fair, though I think payers would see it differently. The real-world impact is undeniable. Subcutaneous administration expands the treatable population — patients with vascular access issues or infusion center limitations can now access therapy. That changes the eligible population calculation for cost-effectiveness models.

MarcusThe part that gives me pause is the comparability. We don't have head-to-head data showing bioequivalence between IV and subQ formulations. If the pharmacokinetic profiles differ, the entire value proposition shifts. Manufacturers will need robust RWE studies to demonstrate real-world outcomes equivalence.

SaraExactly, and what's interesting is how this intersects with NICE's ongoing appraisal. Their draft guidance already questioned the cost-effectiveness of the IV formulation. With subQ potentially reducing administration costs, the ICER threshold conversation becomes even more complex. Will this be enough to tip the scales?

MarcusThis is one of those stories where the innovation outpaces the evidence framework. The FDA approval was based on bioavailability data, not new clinical endpoints. HEOR teams must now build evidence bridges between administration routes. The risk is that payers view this as a minor formulation change rather than a significant access improvement.

SaraI keep coming back to the patient perspective. For caregivers, reducing infusion visits from every two weeks to every four weeks is transformative. But how do we quantify that in QALYs? The HEOR community needs to develop validated PRO measures that capture caregiver burden — that's where the real value argument lies.

MarcusNow the FTC settlement with CVS Caremark over insulin pricing. This is a landmark case where the FTC challenged a PBM's practices regarding insulin reimbursement passes. The core issue: whether PBMs are effectively creating price discrimination between insured and uninsured patients.

SaraThat's one read — I'd frame it slightly differently. What strikes me is the precedent this sets for PBM transparency. The settlement requires CVS to provide clear information about insulin pricing and reimbursement passes. This could force PBMs to operate with more transparency across all drug classes, not just insulin.

MarcusThat's fair, though I think the industry would see it differently. The real story here is the direct market access impact. By limiting PBM spread pricing practices, manufacturers may have more control over list pricing. This could theoretically reduce rebates and create more predictable pricing for payers. But the evidence on whether that translates to lower net prices is still unclear.

SaraThe part that gives me pause is the timing. With the IRA insulin price caps already in place, this settlement feels like overlapping regulation. We're seeing a patchwork of federal and state interventions that create conflicting incentives for manufacturers. The HEOR evidence must now navigate this complex regulatory landscape.

MarcusExactly, and what's interesting is how this connects to value-based contracting. PBMs traditionally resist outcomes-based agreements because they complicate rebate structures. If this settlement reduces PBM discretion in pricing, manufacturers might gain leverage to push for more innovative contracting models that align incentives.

SaraI wonder if that's the full picture though. The settlement also highlights the growing tension between PBMs and pharmacy benefit managers. As PBMs face more scrutiny, they may shift cost burdens to manufacturers through stricter formulary placement requirements. That could increase the evidence burden for new entrants in the insulin market.

MarcusThis is one of those stories where the policy moves faster than the evidence. We need real-world data on how these settlements actually affect patient access. Are insulin costs truly decreasing, or are they just being redistributed? The HEOR community must track these outcomes to inform future policy decisions.

SaraFinally, ICER's expanded scientific advice program. They're increasing the number of advice slots and broadening the scope to include earlier-stage technologies. This is a significant development in how we approach early evidence generation.

MarcusI'd push back slightly on that characterization. While the capacity increase is real, the quality of advice remains the critical factor. ICER's methodological rigor has been questioned in certain areas. Expanding volume without addressing methodological consistency could dilute the value of their advice.

SaraThat's fair, though I think manufacturers would see it differently. The real story here is access to early feedback. Companies developing novel technologies like gene therapies or digital therapeutics often lack clear pathways for payer engagement. ICER's expansion provides crucial early signals that can shape development pathways.

MarcusThe part that gives me pause is the resource allocation. ICER's advice program is already stretched thin. Expanding scope without proportional resource increases could lead to superficial assessments. We need to ensure that the advice remains substantive rather than becoming a checkbox exercise.

SaraExactly, and what's interesting is how this intersects with global HTA collaboration. If ICER's advice becomes more influential internationally, it could create harmonization opportunities. But that requires consistent methodologies across jurisdictions. The expanded program might actually accelerate global convergence if implemented carefully.

MarcusThis is one of those stories where the innovation meets implementation challenges. The HEOR community needs to develop standardized frameworks for evaluating early-stage evidence. Without that, the expanded advice program could create more confusion than clarity.

SaraI keep coming back to the patient perspective. Earlier payer engagement means faster access for promising therapies. But we must balance speed with rigor. The expanded program needs clear quality metrics to maintain credibility. That's what will ultimately determine its impact on patient access.

SaraA lot to think about today. I'll be watching how HCA's financial pressure translates to formulary restrictions across hospital networks. That could be a leading indicator for broader access challenges.

MarcusSame — and for me the thread running through today is the growing complexity of evidence generation. From administration routes to PBM practices, the HEOR field must develop more sophisticated models to capture real-world value. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.